Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Khushboo A. Gandhi"'
Autor:
Soumika Sengupta, Mainak Biswas, Khushboo A. Gandhi, Saurabh Kumar Gupta, Poonam B. Gera, Vikram Gota, Avinash Sonawane
Publikováno v:
Translational Oncology, Vol 43, Iss , Pp 101909- (2024)
Introduction: Escherichia coli l-asparaginase (EcA), an integral part of multi-agent chemotherapy protocols of acute lymphoblastic leukemia (ALL), is constrained by safety concerns and the development of anti-asparaginase antibodies. Novel variants w
Externí odkaz:
https://doaj.org/article/420e0a755d944a7ea447b4bd35e7d0d8
Autor:
Suja Johnson, Chetan Dhamne, Hari Sankaran, Khushboo A. Gandhi, Pallavi Rane, Nirmaly Roy Moulik, Shraddha Mahesh Jadhav, Murari Gurjar, Gaurav Narula, Shripad Banavali, Vikram Gota
Publikováno v:
Cancer Chemotherapy and Pharmacology. 90:445-453
L-asparaginase is an essential medicine for childhood ALL. The quality of generic L-asparaginase available in India is a matter of concern. We compared four commonly used generic formulations of L-asparaginase in India.We conducted a prospective, ope
Autor:
Dievya, Gohil, Girish Ch, Panigrahi, Saurabh Kumar, Gupta, Khushboo A, Gandhi, Poonam, Gera, Preeti, Chavan, Deepak, Sharma, Santosh, Sandur, Vikram, Gota
Publikováno v:
Drug and Chemical Toxicology. :1-14
5-hydroxy-1,4-naphthoquinone (5NQ) or juglone is a bioactive molecule found in walnuts and has shown therapeutic effects in various disease models. Limited information is available regarding the toxicity of 5NQ, thereby limiting the clinical developm
Autor:
Vishwa Vipulkumar Gandhi, Khushboo Atulkumar Gandhi, Jayant Sastri Goda, Liladhar Baburao Kumbhare, Vikram Gota, Amit Kunwar
Publikováno v:
IUBMB Life.
Autor:
Khushboo A. Gandhi, Amit Joshi, Parsshava Mehta, Murari Gurjar, Pallavi Rane, Jyoti Sharma, Anand Patil, Manjunath Nookala, Vanita Noronha, Kumar Prabhash, Vikram Gota
Publikováno v:
Cancer chemotherapy and pharmacology. 89(6)
Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). High variability in pharmacokinetics coupled with a proven exposure-effect relationship makes sunitinib an ideal candidate for therap